EP2903643A4 - TREATMENT OF PSYCHIATRIC DISEASES - Google Patents

TREATMENT OF PSYCHIATRIC DISEASES

Info

Publication number
EP2903643A4
EP2903643A4 EP13843079.8A EP13843079A EP2903643A4 EP 2903643 A4 EP2903643 A4 EP 2903643A4 EP 13843079 A EP13843079 A EP 13843079A EP 2903643 A4 EP2903643 A4 EP 2903643A4
Authority
EP
European Patent Office
Prior art keywords
treatment
psychiatric disorders
psychiatric
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13843079.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2903643A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of EP2903643A1 publication Critical patent/EP2903643A1/en
Publication of EP2903643A4 publication Critical patent/EP2903643A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
EP13843079.8A 2012-10-04 2013-10-01 TREATMENT OF PSYCHIATRIC DISEASES Withdrawn EP2903643A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Publications (2)

Publication Number Publication Date
EP2903643A1 EP2903643A1 (en) 2015-08-12
EP2903643A4 true EP2903643A4 (en) 2016-06-15

Family

ID=50435375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13843079.8A Withdrawn EP2903643A4 (en) 2012-10-04 2013-10-01 TREATMENT OF PSYCHIATRIC DISEASES

Country Status (7)

Country Link
EP (1) EP2903643A4 (OSRAM)
JP (3) JP6750941B2 (OSRAM)
KR (1) KR20150064091A (OSRAM)
CN (1) CN104684581A (OSRAM)
AU (1) AU2013327498B2 (OSRAM)
CA (1) CA2886757C (OSRAM)
WO (1) WO2014055541A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN110382001A (zh) 2017-02-16 2019-10-25 埃克斯生物科技公司 化脓性汗腺炎的治疗
EP4615135A1 (en) 2022-11-04 2025-09-10 Panasonic Intellectual Property Corporation of America Terminal, base station, communication method, and integrated circuit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2694107T3 (en) * 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Antibody Engineering", 1 January 1995, article MORRISON SHERIE L ET AL: "Vectors and Approaches for the Eukaryotic Expression of Antibody Fusion Proteins", pages: 257 - 271, XP093030666 *
"Sequences of Proteins of Immunological Interest", 1 January 1991, article ELVIN A. KABAT ET AL: "Sequences of Proteins of Immunological Interest", pages: FP1-2,iv,661,662,671,680, XP055374199 *
CARRASCO DANIEL ET AL: "An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity", JOURNAL OF DRUGS IN DERMATOLOGY, STRATEGIC COMMUNICATION IN DERMATOLOGY, NEW YORK, NY, US, vol. 14, no. 6, 1 June 2015 (2015-06-01), pages 560 - 564, XP009188540, ISSN: 1545-9616 *
CHARLES A. DINARELLO ET AL: "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no. 8, 1 August 2012 (2012-08-01), pages 633 - 652, XP055051238, ISSN: 1474-1776, DOI: 10.1038/nrd3800 *
GRAHAME V ET AL: "The psychological correlates of treatment efficacy in acne", DERMATOLOGY AND PSYCHOSOMATICS 2002 CH, vol. 3, no. 3, 2002, pages 119 - 125, XP009189887, ISSN: 1422-9196 *
K. SZABÓ ET AL: "Interleukin-1A +4845(G> T) polymorphism is a factor predisposing to acne vulgaris", TISSUE ANTIGENS., vol. 76, no. 5, 11 November 2010 (2010-11-11), DK, pages 411 - 415, XP055270523, ISSN: 0001-2815, DOI: 10.1111/j.1399-0039.2010.01530.x *
ROSSI SILVIA ET AL: "Interleukin-1 beta Causes Anxiety by Interacting with the Endocannabinoid System", JOURNAL OF NEUROSCIENCE, vol. 32, no. 40, 3 October 2012 (2012-10-03), pages 13896 - 13905, XP002757320, ISSN: 0270-6474 *
RUBINOW D R ET AL: "Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 17, no. 1, 1 July 1987 (1987-07-01), pages 25 - 32, XP025650586, ISSN: 0190-9622, [retrieved on 19870701], DOI: 10.1016/S0190-9622(87)70166-2 *
See also references of WO2014055541A1 *
YESIM KAYMAK ET AL: "Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 48, no. 1, 1 January 2009 (2009-01-01), UK, pages 41 - 46, XP055269926, ISSN: 0011-9059, DOI: 10.1111/j.1365-4632.2009.03806.x *

Also Published As

Publication number Publication date
WO2014055541A1 (en) 2014-04-10
JP2015531396A (ja) 2015-11-02
AU2013327498A1 (en) 2015-04-02
EP2903643A1 (en) 2015-08-12
CA2886757C (en) 2022-04-05
AU2013327498B2 (en) 2018-06-28
JP2022177132A (ja) 2022-11-30
CN104684581A (zh) 2015-06-03
JP6750941B2 (ja) 2020-09-02
KR20150064091A (ko) 2015-06-10
CA2886757A1 (en) 2014-04-10
JP2020143133A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
IL269511A (en) New therapeutic approaches for treating parkinson's disease
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
EP2819703A4 (en) PAIN TREATMENT
EP2854769A4 (en) METHOD FOR THE TREATMENT OF ARTHRITIS
EP2911682A4 (en) METHOD FOR TREATING ANEMIA
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
EP2635299A4 (en) METHOD FOR TREATING HAIR LOSS
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2825898A4 (en) AUDIO SOURCE PROCESSING
EP2566520A4 (en) METHOD FOR TREATING IL1-MEDIATED INTERFERENCE
IL228030B (en) Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia
EP2771007A4 (en) TREATMENT OF RHINITIS
EP2906580A4 (en) TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
EP2903643A4 (en) TREATMENT OF PSYCHIATRIC DISEASES
HRP20181481T1 (hr) D-metadon za liječenje psihijatrijskih simptoma
EP2976094A4 (en) METHOD FOR THE TREATMENT OF METABOLISM TROUBLES
EP2841080A4 (en) COMPOSITION FOR THE TREATMENT OF METABOLISM DISORDERS
EP2694107A4 (en) TREATMENT OF DERMATOLOGICAL SUFFERING
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
EP2922534A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES
IL234606B (en) Novel methods and composition for treatment of disease
EP2750709A4 (en) TREATMENT OF KACHEXIE
EP2673363A4 (en) TREATMENT OF ANGIOGENESE COMMANDS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160518

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/24 20060101ALI20160509BHEP

Ipc: A61K 39/395 20060101AFI20160509BHEP

Ipc: A61P 17/10 20060101ALI20160509BHEP

Ipc: A61P 25/00 20060101ALI20160509BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIMARD, JOHN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200702

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JANSSEN BIOTECH, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230915